Mr. LaCaze Brings Over 35 Years of Executive
Leadership Experience in the Biopharmaceutical Industry
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the
“Company”) today announced that Robert LaCaze has joined Summit
Therapeutics as Chief Commercial Officer, reporting to Manmeet S.
Soni, Chief Operating Officer and Chief Financial Officer,
effective immediately.
Robert W. Duggan and Dr. Maky Zanganeh, Co-CEOs of Summit
Therapeutics, stated, “Robert’s extensive experience and proven
track record in the oncology space make him an exceptional addition
to our team. His leadership will be instrumental as we seek to
bring ivonescimab to patients in need. We are truly excited to have
him on board and look forward to the positive impact he will have
on our commercial efforts.”
Robert LaCaze is a seasoned biopharmaceutical executive with
over 35 years of extensive leadership experience in commercial
strategy and execution, with a proven track record of driving
revenue growth and expanding market presence for various oncology
products. He has held senior positions at major pharmaceutical
companies like Bayer Healthcare and Bristol-Myers Squibb. At Bayer,
he served as Executive Vice President and Head of the Oncology
Strategic Business Unit, overseeing the global oncology franchise
and serving on the Executive Committee for Bayer Pharmaceuticals.
Before that, he was Senior Vice President and Head of Global
Oncology at Bristol-Myers Squibb, leading the vision, strategy, and
execution of the immuno-oncology franchise.
“We are delighted to welcome Mr. LaCaze to Summit Therapeutics.
His vast experience and visionary leadership in building oncology
commercial teams at large pharmaceutical companies will be
invaluable as we continue our potential commercial launch of
ivonescimab,” added Manmeet Soni. “We are confident that Mr.
LaCaze’s strategic insights and operational expertise will
significantly enhance our ability to execute on our mission to
build a viable health care organization intended to improve quality
of life, increase potential duration of life, and resolve serious
medical needs.”
Mr. LaCaze has experience across various therapeutic areas and
modalities, including biologics, cell therapies,
radiopharmaceuticals, and diagnostics. He has a proven track record
of launching multi-billion-dollar products and building and growing
blockbuster drug franchises. Prior to joining Summit, Mr. LaCaze
was CEO and President of Mnemo Therapeutics. He has served on
various advisory boards and received numerous awards, including
being named a Top 25 Healthcare Technology Leaders of New Jersey
for 2022 by The Healthcare Technology Report. Additionally, he
serves on the Board for Axiom REACH, a non-profit organization
aiding underprivileged cancer patients. Mr. LaCaze received a
Bachelor of Science in Marketing from Louisiana Tech
University.
“I am thrilled to join Team Summit and contribute to the
organization’s next steps,” added Mr. LaCaze. “Summit's commitment
to excellence and its highly-accomplished team provide me with
great confidence about what can be achieved with such an
innovative, novel product candidate, ivonescimab. I look forward to
working with the team to help drive a successful commercial launch
of ivonescimab and the potential to make a meaningful impact in the
lives of patients with cancer.”
About Summit Therapeutics
Summit Therapeutics Inc. is a biopharmaceutical oncology company
focused on the discovery, development, and commercialization of
patient-, physician-, caregiver- and societal-friendly medicinal
therapies intended to improve quality of life, increase potential
duration of life, and resolve serious unmet medical needs.
Summit was founded in 2003 and our shares are listed on the
Nasdaq Global Market (symbol "SMMT"). We are headquartered in
Miami, Florida, and we have additional offices in Menlo Park,
California, and Oxford, UK.
For more information, please visit https://www.smmttx.com and
follow us on X @SMMT_TX.
Summit Forward-looking Statements
Any statements in this press release about the Company’s future
expectations, plans and prospects, including but not limited to,
statements about the clinical and preclinical development of the
Company’s product candidates, entry into and actions related to the
Company’s partnership with Akeso Inc., the intended use of the net
proceeds from the private placements, the Company's anticipated
spending and cash runway, the therapeutic potential of the
Company’s product candidates, the potential commercialization of
the Company’s product candidates, the timing of initiation,
completion and availability of data from clinical trials, the
potential submission of applications for marketing approvals,
potential acquisitions, statements about the previously disclosed
At-The-Market equity offering program (“ATM Program”), the expected
proceeds and uses thereof, and other statements containing the
words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "would," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including the
Company’s ability to sell shares of our common stock under the ATM
Program, the conditions affecting the capital markets, general
economic, industry, or political conditions, the results of our
evaluation of the underlying data in connection with the
development and commercialization activities for ivonescimab, the
outcome of discussions with regulatory authorities, including the
Food and Drug Administration, the uncertainties inherent in the
initiation of future clinical trials, availability and timing of
data from ongoing and future clinical trials, the results of such
trials, and their success, global public health crises, that may
affect timing and status of our clinical trials and operations,
whether preliminary results from a clinical trial will be
predictive of the final results of that trial or whether results of
early clinical trials or preclinical studies will be indicative of
the results of later clinical trials, whether business development
opportunities to expand the Company’s pipeline of drug candidates,
including without limitation, through potential acquisitions of,
and/or collaborations with, other entities occur, expectations for
regulatory approvals, laws and regulations affecting government
contracts and funding awards, availability of funding sufficient
for the Company’s foreseeable and unforeseeable operating expenses
and capital expenditure requirements and other factors discussed in
the "Risk Factors" section of filings that the Company makes with
the Securities and Exchange Commission. Any change to our ongoing
trials could cause delays, affect our future expenses, and add
uncertainty to our commercialization efforts, as well as to affect
the likelihood of the successful completion of clinical development
of ivonescimab. Accordingly, readers should not place undue
reliance on forward-looking statements or information. In addition,
any forward-looking statements included in this press release
represent the Company’s views only as of the date of this release
and should not be relied upon as representing the Company’s views
as of any subsequent date. The Company specifically disclaims any
obligation to update any forward-looking statements included in
this press release.
Summit Therapeutics and the Summit Therapeutics
logo are trademarks of Summit Therapeutics Inc. Copyright 2025,
Summit Therapeutics Inc. All Rights Reserved.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250317175356/en/
Contact Summit Therapeutics: Dave Gancarz Chief Business
& Strategy Officer
Nathan LiaBraaten Senior Director, Investor Relations
investors@smmttx.com media@smmttx.com
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Mar 2025 to Apr 2025
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Apr 2024 to Apr 2025
